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Abstract
Background: The objective of this study was to explore the associations between ultrasonographic and radiographic
joint scores and levels of arterial CVD risk markers in patients with osteoarthritis (OA). Secondly, to compare the levels
of arterial CVD risk markers between OA phenotypes and controls.
Method: The “Musculoskeletal pain in Ullensaker” Study (MUST) invited residents of Ullensaker municipality
with self-reported OA to a medical examination. OA was defined according to the American College of
Rheumatology (ACR) criteria and phenotyped based on joint distribution. Joints of the hands, hips and knees
were examined by ultrasonography and conventional radiography, and scored for osteosteophytes. Hands
were also scored for inflammation by grey scale (GS) synovitis and power Doppler (PD) signal. Control
populations were a cohort of inhabitants of Oslo (OCP), and for external validation, a UK community-based
register (UKPC).
Pulse pressure augmentation index (AIx) and pulse wave velocity (PWV) were measured using the Sphygmocor
apparatus (Atcor®). Ankel-brachial index (ABI) was estimated in a subset of patients. In separate adjusted regression
models we explored the associations between ultrasonography and radiograph joint scores and AIx, PWV and ABI. CVD
risk markers were also compared between phenotypes of OA and controls in adjusted analyses.
Results: Three hundred and sixty six persons with OA were included (mean age (range); 63.0 (42.0–75.0)), (females (%);
264 (72)). Of these, 155 (42.3%) had isolated hand OA, 111 (30.3%) had isolated lower limb OA and 100 (27.3%) had
generalized OA. 108 persons were included in the OCP and 963 persons in the UKPC; (mean age (range); OCP: 57.2
(40.4–70.4), UKPC: 63.9 (40.0–75.0), females (%); OCP: 47 (43.5), UKPC: 543 (56.4%). Hand osteophytes were associated
with AIx while GS and PD scores were not related to CVD risk markers. All OA phenotypes had higher levels of AIx
compared to OCP in adjusted analyses. External validation against UKPC confirmed these findings.
Conclusions: Hand osteophytes might be related to higher risk of CVD. People with OA had higher augmented
central pressure compared to controls.
Words 330.
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Background
Osteoarthritis (OA) is a prevalent disease, characterized
by derangement of the whole joint. The classification
criteria are clinical and radiographic [1–3]. The preva-
lence of OA in an urban European population aged ≥55
years has been estimated, OA of the distal inter-phalan-
geal joint was most common with 33% being afflicted,
knee OA was present in 15% while hip OA was found in
6% [4]. Ultrasonography is useful for the detection of
osteophytes and current inflammation at the joint level,
the latter visualised by grey scale (GS) synovitis and
power Doppler (PD) signal.
Cardiovascular disease (CVD) accounts for over 60%
of deaths in OA populations [5], and there is evidence of
increased all-cause, and cardiovascular disease (CVD)
related, mortality in OA [4, 6, 7]. The increased risk of
CVD is often attributed to the established covariation
between OA and established risk factors of CVD such as
decreased physical activity, increased body mass index
(BMI) and prevalent use of non-steroid anti-inflamma-
tory drugs (NSAIDs) [5, 8]. Vascular pathology as a
result of low level inflammation at the joint level is how-
ever a causal pathway that is also debated [6]. Arterial
stiffening is a pathophysiological step in CVD deve-
lopment, and a predictor of CVD mortality [9]. The gold
standard of arterial stiffness evaluation is pulse wave ve-
locity (PWV) and the relative risk (RR) for CV mortality
increases by 15% (95% CI 9–21) for each 1 m/s increase
in PWV [10]. The augmentation index (AIx) is a mea-
sure of central pressure augmentation and also an in-
dependent risk factor of CVD events and mortality, and
the relative risk of CV events is estimated to increase by
32% (95% CI 9–59) for each 10% increase in AIx [11].
Ankle-brachial index (ABI) is a validated marker of CVD
risk [12]. At cut-off of 0.9 is most frequently used for
ABI but the mortality rate falls linearly with increasing
ABI until a floor is reached at an ABI of approximately
1.1. There is some indication of an increased mortality
rate if ABI > 1.4. An ABI < 0.9 is associated with an in-
creased risk of CVD, with an OR for CV event between
1.3 and 4.2 reported in a review of 9 papers [12].
The objectives of this study were to investigate the
association between radiographic and ultrasonographic
joint scores in OA and CVD risk markers. Secondly, to
compare CVD risk markers between phenotypes of
OA and population controls, adjusting for possible
confounders.
Methods
The musculoskeletal pain in Ullensaker study (MUST)
Residents of Ullensaker municipality (Norway), aged 42–
80 years, with self-reported OA were invited to a com-
prehensive data-collection including medical examin-
ation (details previously published [13]). Individuals aged
between 42 and 75 were selected for this study. The
MUST study was approved by the Norwegian Regional
Committee for Medical and Health Research Ethics
South East (reference numbers 2009/812 and 2009/
1703) and the participant gave their written informed
consent according to the Declaration of Helsinki prior
to inclusion.
Oslo community controls (OCP)
A random sample of 329 adult inhabitants of Oslo
(Norway), aged 20–70, were selected by Statistics
Norway, and individuals without an inflammatory joint
disease were invited to a cardiovascular risk assessment
at Diakonhjemmet Hospital. ABI, radiography and US
joint examinations were not performed in this cohort
[14]. In total 134 (41%) consented. The OCP was
approved by the Norwegian Regional Committee for
Medical and Health Research Ethics South East (refer-
ence numbers 2009/1703) and the participants gave their
written informed consent according to the Declaration
UK population controls (UKPC)
For external validation of our findings we used anon-
ymised data from The Anglo-Cardiff Collaborative Trial.
This was a community population-based study of ≈ 12,
000 individuals drawn from General Practice lists or
open access cardiovascular risk assessment units in East-
Anglia and Wales, United Kingdom. The response rate
was 85%. From this cohort a random sample of 963
cases, aged 40–75 years, without self-reported inflamma-
tory rheumatic disease or OA was included.
Joint examinations (MUST only)
In MUST, hand, knee and hip joints were examined and
radiographs of hands, knees and hips taken as previously
described [13]. Radiographic OA severity was scored ac-
cording to the Kellgren-Lawrence (KL) scale (grade 0–4)
for hands (distal and proximal interphalangeal, metacar-
phalangeal and first carpometacarpal joints), hip and
knee joints. OA was defined according to the American
College of Rheumatology (ACR) classification criteria
[1–3]. For hand OA, only clinical variables are included
in the criterion, whereas both clinical and radiographic
variables are included in the criteria for hip and knee
OA. When radiographs were missing, the clinical ACR
criterion for knee OA was used if sufficient data was
available. The cut-offs for joint space narrowing (JSN)
and osteophytes in the ACR criterion for hip joints were
grade ≥ 1 according to the Osteoarthritis Research
Society International atlas [15]. Knee osteophytes were
defined as KL grade ≥ 2. Persons with hip or knee pros-
thesis were classified as having OA in the respective
joint. Participants were categorised according to the
following OA phenotypes based on the fulfilment of the
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ACR criteria: 1) Isolated hand OA, 2) Isolated OA in
lower limbs (i.e. knee and/or hip OA), 3) Generalized
OA, defined as OA in both hands and lower limbs.
The protocol for ultrasonography and conventional ra-
diographs of bilateral hands, knees and hips has been
previously described [13]. Osteophytes GS and PD were
semi-quantitatively scored on 0–3 scales (0 = none, 1 =
minor, 2 = moderate and 3 =major presence of US path-
ology). Sum scores for ultrasound defined osteophytes
were calculated for hands (range 0–90) and hips/knees
(range 0–30), GS and PD in the hands (range 0–90) and
GS hips/knees (range 0–4). KL sum scores were calcu-
lated for the hands (range 0–120) and hips/knees (range
0–16).
Biomarkers of CVD risk
Pulse wave analyses (PWV and AIx) were performed
using the Sphygmocor apparatus (Atcor®) by trained
Fig 1 a AIx across OA phenotypes and controls (Age and gender adjusted modesl) Vertical axis: Estimated marginal means AIx. b AIx across OA
phenotypes and controls (Fully adjusted models) Vertical axis: Estimated marginal means AIx. AIx; augmentation index OA; osteoarthritis Gen;
general, OCP; Oslo community population, UKPC; United Kingdom Community population. Footnotes a HandOA vs OCP p = 0.03, vs. UKPC
p = 0.001, LowerLimbOA vs OCP p = 0.06, vs. UKPC p = 0.002, GenOA vs. OCP p = 0.02, vs. UKPC p < 0.001, HandOA vs LowerLimbOA p = 0.73,
HandOA vs GenOA p = 0.74, GenOA vs LowerLimbOA p = 0.51. b HandOA vs OCP p = 0.004, vs. UKPC p < 0.001, LowerLimbOA vs OCP p = 0.04,
vs. UKPC p = 0.007, GenOA vs. OCP p = 0.009, vs. UKPC p = 0.001, HandOA vs LowerLimbOA p = 0.44, HandOA vs GenOA p = 0.95, GenOA vs
LowerLimbOA p = 0.50
Provan et al. BMC Rheumatology            (2019) 3:33 Page 3 of 9
personnel using the same methodology for all cohorts
(MUST, OCP and UKPC) [13, 16]. ABI was measured in
a standardized fashion. To obtain the ABI, the systolic
pressure was estimated by a Sonotrax - Pocket Doppler
Vascular - 8MHz probe in the posterior tibial and dorsa-
lis pedis arteries in both legs and in the brachial artery
in one arm. The highest pressure recorded in either
artery was recorded as the measurement for that side.
The lowest of the distal pressures (ankle) measured
either at the right or the left side was then divided by
the brachial systolic pressure [12].
In MUST recordings of AIx were available in 258
(70.5%), PWV in 257 (70.2%) and ABI in 174 (47.5%)
persons. Missing PWA recordings were related to logis-
tical limitations of the study, unavailability of the PWA
investigator and/or poor data quality according to prede-
fined criteria. Due to time limitations ABI was recorded
in every other patient as previously described [13]. In
OPC, AIx was available in 104 (96.2%) and PWV in 97
(89.8%) of the participants. All UKPC participants had
available AIx and PWV. ABI was not assessed in OCP
and UKPC.
Covariates
All cohorts had information concerning age, gender
body mass index (BMI) measured in kg/m2, C-reactive
protein (CRP) measured as mg/L and smoking status,
dichotomized as daily smoker vs. non-daily smoker or
non-smoker. MUST and OCP also had information on
level of education, dichotomized as college or university
education vs. high school or lower education, use of
non-steroidal anti-inflammatory drugs (daily vs. non-
daily or never), physical functioning by the Modified
Health Assessment Questionnaire (MHAQ) and self-re-
ported exercise habits (> = once a week vs. < once a
week) [13].
Statistics
This study was designed as a cross-sectional case-control
study, with two separate control populations. Variables
were visually examined for normality, and kurtosis and
skewness were calculated. Baseline demographics were
compared using chi-square tests, independent samples
Student’s t-test or Mann-Whitney U-test as appropriate.
In linear regression models we examined the associa-
tions between ABI, AIx, PWV (dependent variables) and
the severity of OA using ultrasonography and radio-
graphic and sum scores. The estimated marginal means
of AIx and PWV were estimated and compared between
OA phenotypes, OCP and UKPC. ABI was compared
between OA phenotypes. The associations between AIx,
PWV, ABI and all covariates were tested in age and gen-
der adjusted models, andco-variates associated with the
dependent outcome with a p < = 0.01 were included in


























Female gender, n (%) 366 126 (81.3) 62 (55.9) 76 (76.0) < 0.001 0.002 0.31
Smoking daily, n (%) 363 18 (11.7) 13 (11.9) 12 (12.0) 0.95 0.99 0.94
Higher education, n
(%)
359 37 (24.5) 41 (37.3) 26 (26.5) 0.03 0.10 0.72
BMI kg/m2, mean (SD) 356 25.8 (4.3) 28.0 (4.7) 28.1 (4.7) < 0.001 0.77 < 0.001
CRP mg/L, mean (SD) 364 2.2 (3.5) 2.6 (4.4) 2.9 (3.8) 0.44 0.64 0.17
Use of NSAIDs daily
n (%)
364 27 (17.4) 20 (18.2) 20 (20.2) 0.87 0.71 0.58
Heart rate, beats/min
(SD)
258 64.4 (10.4) 63.7 (9.8) 65.4 (10.7) 0.63 0.29 0.56







Regular exercise n (%) 365 137 (77.4) 101 (91.0) 87 (87.9) 0.50 0.46 0.90
AIx,% mean (SD 258 32.3 (8.5) 29.0 (8.9) 31.7 (8.6) 0.01 0.05 0.67
PWV m/s, mean (SD) 257 8.65 (2.0) 8.7 (1.9) 9.1 (2.0) 0.61 0.25 0.11
ABI 174 1.2 (0.1) 1.2 (0.1) 1.2 (0.2) 0.02 0.46 0.14
Unadjusted bivariate models. The Chi square, independent samples Student T-test or independent samples
Mann-Whitney U-test were used as appropriate
N number, BMI body mass index, CRP C-reactive protein, NSAIDs non-steroidal anti-inflammatory drugs, AIx augmentation index, PWV pulse wave velocity, BP
blood pressure. MUST-OA persons in MUST with osteoarthritis, OCP Oslo community controls, UKPC UK population controls
Provan et al. BMC Rheumatology            (2019) 3:33 Page 4 of 9
the final models. AIx models were also adjusted for heart
rate and height. PWV models were adjusted for heart
rate.
Missing data was not imputed, but a comparison of
demographics between participants with available vs.
missing PWA and ABI was performed. Cooks distances
were calculated and outliers examined.
Result
We examined 630 persons with self-reported OA and
of these 366 persons with OA were identified. Of the
366 persons; 155 (42.3%) had isolated hand OA ac-
cording to the ACR criteria, 111 (30.3%) had isolated
lower limb OA, and 100 (27.3%) had generalized OA.
Details of the selection procedure are presented in
Fig. 1. Demographic and clinical characteristics of the
OA phenotypes of the persons included in the MUST
are presented in Table 1, and for OCP and UKPC in
Additional file 1: Table S1. Persons with generalized
OA were significantly older than persons with isolated
hand OA, while persons with isolated lower limb OA
were significantly less likely to be female.
Severity of structural OA changes in the hands (KL
sum score and US-defined osteophytes) was significantly
associated with AIx. However, neither synovitis (hand
GS and PD, and lower limb GS), nor osteophytes in the
lower limbs (hip and knee KL sum scores and US-de-
fined osteophyte hip and knee sum score) were signifi-
cantly associated with the CVD risk markers (Table 2).
Participants with OA had higher AIx compared to
OCP and UKPC, regardless of phenotype (Fig. 1a). The
final multivariate model for AIx also adjusted for smok-
ing, but this did not significantly change the main effect
(Fig. 1b). PWV and ABI were not increased in patient
with OA compared to OCP and UKPC (Fig. 2a and 3a).
The final model for PWV adjusted for BMI, but this did
not alter the lack of association between OA and PWV
(Fig. 2b). None of the covariates were significantly asso-
ciated to ABI in the final model, except for gender.
There were no significant differences in AIx, PWV or
ABI between the OA phenotypes.
Table 2 The association between CVD vascular biomarkers, demographics, covariates and OA radiographic and ultrasonographic
variables
CVD risk markers (dependent variables)
AIx β (95% CI) PWV β (95% CI) ABI β (95% CI)
Patients in MUST, OPC and UKPC Only MUST
Age years, mean (range) 0.27 (0.21–0.33)** 0.12 (0.11–0.13)** − 0.00 (− 0.01–0.00)
Female gender, n (%) 6.38 (5.26–7.49)* − 0.22 (− 0.42- -0.02)* − 0.10 (− 0.15—0.06)**
Smoking daily, n (%) 3.60 (2.19–5.01)** 0.15 (− 0.20–0.50) − 0.05 (− 0.11–0.02)
Higher education, n (%) −0.06 (− 1.77–1.65) − 0.03 (− 0.39–0.32) 0.02 (− 0.02–0.06)
BMI kg/m2, mean (SD) −0.05 (− 0.14–0.04) 0.06 (0.04–0.09)** 0.00 (− 0.00–0.01)
CRP mg/L, mean (SD) − 0.02 (− 0.10–0.06) 0.03 (0.01–0.05)* 0.00 (− 0.00–0.00)
Use of NSAIDs 1.00 (− 1.11–3.11) 0.14 (− 0.31–0.58) − 0.02 (− 0.07–0.03)
MHAQ 1.30 (−1.79–4.38) − 0.16 (− 0.80–0.48) −0.00 (− 0.68–0.07)
Regular exercise n (%) −1.59 (− 3.63–0.45) −0.10 (0.53–0.34) −0.02 (0.08–0.05)
Heart rate (beats/min) −0.45 (− 048- -0.41)** 0.04 (0.03–0.05)** −0.00 (− 0.00–0.00)
Patients in MUST only Only MUST
Radiographic osteophytes
Hand KL
0.07 (0.01–0.13)* 0.00 (−0.01–0.02) 0.00 (− 0.00–0.00)
Radiographic osteophytes
Lower limb
− 0.19 (− 0.66–0.29) −0.04 (− 0.15–0.07) 0.01 (0.00–0.02)*
US PD Hand 0.41 (− 1.45–2.27) 0.05 (− 0.36–0.46) −0.01(− 0.05–0.03)
US GS Hand 0.28 (− 0.06–0.63) −0.04 (− 0.12–0.03) 0.00 (− 0.00–0.01)
US GS Lower limb −0.84 (− 2.64–0.96) −0.06 (− 0.47–0.34) 0.01 (− 0.03–0.05)
US osteophytes Hand 0.09 (0.02–0.16)* −0.00 (− 0.00–0.00) 0.00 (− 0.00–0.00)
US osteophytes Lower limb 0.07 (−1.39–1.54) −0.19 (− 0.52–0.13) 0.02 (− 0.02–0.05)
Dependent variables in separated models. N number, BMI body mass index, CRP C-reactive protein, NSAIDs non-steroidal anti-inflammatory drugs, AIx
augmentation index, PWV pulse wave velocity. BP blood pressure. MUST-OA persons in MUST with osteoarthritis, OCP Oslo community controls, UKPC UK
population controls, AIx augmentation index, PWV pulse wave velocity, ABI ankle-brachial index
All models adjusted for age and gender. Linear regression models β beta coefficient, CI confidence interval, n number, KL Kellgren Lawrence, PD power Doppler
GS grey scale *p < 0.05**p < 0.00
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Comparisons of persons in MUST with vs. without
CVD risk markers are presented in the Additional file 1:
Table S2. More females than males had missing AIx and
PWV.
Discussion
In this study structural hand OA severity was associated
with AIx, but there were no association between level of
inflammation in the hands, measured by GS and PD,
and other CVD risk markers. Furthermore, participants
with OA had higher levels of AIx compared to OCP
controls, and this finding was confirmed by external
validation against the UKPC.
To our knowledge, we are the first group to investigate
the relationship between US joint scores and CVD risk
markers in people with OA. Vascular pathology has been
hypothesised to be both a risk factor for OA initiation
and development, and a possible consequence of the
changes in extra-cellular matrix and cartilage seen in
OA. Thus, an examination of the association between
vascular CVD-risk markers and OA imaging scores is of
interest [6, 17]. The AIx is considered a more precise
Fig. 2 a PWV across OA phenotypes and controls (Age and gender adjusted models). Vertical axis: Estimated marginal means PWV m/s. b PWV
across OA phenotypes and controls (Fully adjusted models). Vertical axis: Estimated marginal means PWV m/s. PWV; Pulse wave velocity OA;
osteoarthritis Gen; general, OCP; Oslo community population, UKPC; United Kingdom Community population. Footnote a HandOA vs OCP p =
0.61, vs. UKPC p = 0.42, LowerLimbOA vs OCP p = 0.83, vs. UKPC p = 0.22, GenOA vs. OCP p = 0.95, vs. UKPC p = 0.21, HandOA vs LowerLimbOA
p = 0.76, HandOA vs GenOA p = 0.68, GenOA vs LowerLimbOA p = 0.90. b HandOA vs OCP p = 0.68, vs. UKPC p = 0.29, LowerLimbOA vs OCP p =
0.34, vs. UKPC p = 0.72, GenOA vs. OCP p = 0.73, vs. UKPC p = 0.31, HandOA vs LowerLimbOA p = 0.59HandOA vs GenOA p = 0.96, GenOA vs
LowerLimbOA p = 0.58
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estimation of central hemodynamics than brachial pres-
sure, and has also been shown to be a predictor of CVD
that is independent of brachial pressure [11].
In our study CVD risk, measured by increased
levels of AIx, was not associated with acute inflam-
mation at the joint level graded by US, measured by
GS and PD, or with CRP. However, AIx was associ-
ated with structural OA features, which may be con-
sidered the cumulative result of joint inflammation
[18]. In addition, participants with symptomatic hand
OA, fulfilling the ACR criteria, had higher AIx com-
pared to controls. The AGES study from Iceland also
found that carotid plaques and coronary calcium
scores were associated with the severity of hand OA
judged by photographs of the hands [7, 19]. Haugen
et al. found a higher risk of coronary heart disease in
persons with symptomatic hand OA, but not for per-
sons with non-symptomatic radiographic hand OA in
the Framingham study [20].
The severity of lower-limb OA was not significantly
related to CVD risk markers in this study, although pa-
tients with lower limb and general OA did have higher
levels of AIx, compared to controls in our study. There
have been disparate findings on a possible connection
between lower limb OA joint destruction and CVD risk.
Goldsmith et al. reported that bone marrow lesions in
knee OA were not related to the levels of a panel of vas-
cular CVD-risk markers [17]. Belen et al. however, found
that aortic stiffness was correlated to the KL score in
knee OA [21], and Tootsi et al concluded that radio-
graphic OA grade was associated with PWV in a cohort
of patients with end stage knee and hip OA [22].
Large systematic reviews have demonstrated an excess
risk of CVD in persons with OA [5, 6], our study indi-
cates that central augmented pressure, measured by AIx
is increased in patients with OA in general, and particu-
larly in patients with structural hand OA evident as
osteophytes. One possible explanation for the increased
AIx in structural hand OA is that the hands are organs
at the end of a vascular loop, and that change in vascular
resistance as a consequence of structural joint and vas-
cular pathology may increase the wave reflection in the
arteries, thus increasing the augmented pressure. In
contrast, acute inflammation is associated with vascular
dilatation and thus reduced AIx [14].
The clinical relevance of this study is that it identifies
an association between structural hand OA and in-
creased central augmented pressure, which may in the
future lead to patients with OA, and structural hand OA
in particular, receiving anti-hypertensive treatment at an
earlier stage. In patients with lower limb or general OA
the association between CVD risk and structural joint
pathology was not evident, but presence of OA was a-
ssociated with an increased level of central pressure.
Although a possible linkage between joint vascular path-
ology, also in the joints of the lower limb, and risk of
CVD cannot be negated, possible confounders and
mediators must be considered. A strength of our study
Fig. 3 Footnote both figures. ABI; Ankle brachial index Pulse wave velocity OA; osteoarthritis Gen; general. HandOA vs LowerLimbOA p = 0.19,
HandOA vs GenOA p = 0.55, GenOA vs LowerLimbOA p = 0.05
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was that we had the opportunity to examine the associ-
ation between CVD-risk markers and BMI, CRP, smok-
ing, education, physical functioning, physical activity and
use of NSAIDs, and adjust the models when warranted,
but these covariates did not alter the associations.
Other strengths of this study were the comprehensive
data-collection and the heterogeneity of OA phenotypes
in the MUST cohort. A limitation is however that this is
a cross-sectional study and causal relationships cannot
be explored. A further limitation is that the OCP control
cohort was not designed as a comparator for MUST and
although the participants in both MUST and OCP come
from the same region of Norway, the cohorts do not
match perfectly with regards to gender distribution and
age range. We have adjusted for these differences in our
analyses, and we also chose to use the large UKPC for
external validation of our findings. We also acknowledge
that approximately 15% of participants had not per-
formed PWA, and that participants without PWA were
more likely to be female compared to participant where
PWA was available. Despite the gender difference we
believe that the PWA was missing at random due to
logistical challenges of this large study.
Conclusion
Structural hand OA severity might be related to higher
risk of CVD. People with OA had higher augmented
central blood pressure compared to controls.
Additional files
Additional file 1: Table S1. Bivariate comparisons between participants
with OA and UK population controls. Table S2. Comparison between
participants with and without AIx, PWV and ABI. (DOCX 40 kb)
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